Lenalidomid Zentiva (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4‑CRBN ubiquitin‑ligase complex, altering its activity. This triggers degradation of specific transcription factors, leading to reduced proliferation of malignant cells, inhibition of new blood‑vessel formation, and modulation of immune responses that help the body target cancer cells.

The exact dose of Lenalidomid Zentiva is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Healthcare professionals follow approved dosing guidelines and adjust the regimen as needed for safety and efficacy.

Lenalidomid Zentiva is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. Women of childbearing potential must use effective contraception, and the drug should not be used while breastfeeding because it may pass into breast milk.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lenalidomid Zentiva belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration, which can be more convenient, and has demonstrated efficacy in combination regimens, though safety profiles and specific patient suitability differ among therapies.

Lenalidomid Zentiva should be stored at ambient temperature below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Lenalidomid Zentiva is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and should not alter the dose or frequency without medical advice.

The most serious risks include venous thromboembolism, severe cutaneous reactions such as Stevens‑Johnson syndrome, secondary primary malignancies, and profound hematologic toxicities like neutropenia and thrombocytopenia. Prompt medical attention is required if any signs of these conditions appear.

Lenalidomid Zentiva should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled infections or severe hepatic impairment unless specifically advised by a specialist. Clinicians must evaluate each patient’s medical history before initiating therapy.